secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cyclo Therapeutics, Inc. (—)
CIK:        0000922247
Form:       8-K
Filed at:   2025-03-26T23:59:59+00:00
Accession:  0001437749-25-009255
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclo Therapeutics completes merger with Rafael Holdings; delisting from Nasdaq
-------------------------------------------------------------------------------

- Cyclo shareholders received 0.3525 Rafael Class B shares per share, representing ~22% of combined company.
- CYTH and CYTHW trading suspended; company will deregister under Exchange Act Sections 12(b) and 12(g).
- TransportNPC Phase 3 trial fully enrolled; 48-week interim analysis for Niemann-Pick Type C1 expected mid-2025.
- Former Cyclo directors and officers ceased; Markus W. Sieger appointed to Rafael board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/922247/000143774925009255/0001437749-25-009255-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/922247/000143774925009255/ctdh20250324_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-009255

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer